Developments and Prospects of Radiopharmaceuticals in China

doi:10.19803/j.1672-8629.20240570

Abstract

Abstract: Objective To find out about the overall development of radiopharmaceuticals in China and analyze the major obstacles to the production and use of radiopharmaceuticals. Methods In-depth studies were carried out where the radiopharmaceutical industry was concentrated in China, involving drug inspection organizations, manufacturers and medical institutions and based on field visits, literature review and a comparative study. Results and Conclusion It is recommended that the Measures for the Administration of Radiopharmaceuticals be revised as soon as possible, the approval and management of radiopharmaceuticals and medical devices be standardized, radiopharmaceutical testing institutions be upgraded, guidance on research and development of radiopharmaceuticals be increased, so as to promote the healthy,rapid and high-quality development of China's radiopharmaceutical industry.

Key words: Radiopharmaceuticals, High-Quality Develo-pment, Pharmaceutical Inspection Organization, Develo-pment Status, Research and Development, Supervision and Management, Regulatory Science

CLC Number:

R954

LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240570

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I1/37

References

[1] GAO J, ZHENG XB, WANG HL, et al.Development Status and Prospect of Therapeutic Radiopharmaceutical[J]. Journal of Isotopes(同位素), 2022, 35(3): 151-163.
[2] ZHAO DP, CHEN XH, SU W, et al.Application of Radiopharmaceuticals in Clinical Diagnosis and Treatment[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2022, 29(18): 1354-1360.
[3] ZHANG TT, ZHANG H, DI CX.Application of Radiopharmaceuticals in Targeted Tumor Therapies[J]. Chinese Journal of Biochemistry and Molecular Biology(中国生物化学与分子生物学报), 2022, 38(11): 1435-1442.
[4] ZHANG JM, DU J.Preparation of Radiopharmaceuticals in China: Current Status and Prospect[J]. Journal of Isotopes(同位素), 2019, 32(3): 178-185.
[5] SUN DY, JIA JJ, HUANG HW.An Overview of the Radioactive Drugs Approved by FDA During 2011-2022 and the Application Status in China[J]. Chinese Journal of Medicinal Chemistry(中国药物化学杂志), 2023, 33(9): 679-695.
[6] PENG SM, YANG YC, XIE X, et al.Current Status and Prospects of Reactor Produced Medical Radioisotopes in China[J]. Chinese Science Bulletin(科学通报), 2020, 65(32): 3526-3537.
[7] BAKHT MK, H BELTRAN. Biological Determinants of PSMA Expression, Regulation and Heterogeneity in Prostate Cancer[J/OL]. Nature Reviews Urology, (2024-07-08)[2024-08-12]. https://www.nature.com/articles/s41585-024-00900-z.
[8] ZHANG J, LOU LJ, LV R, et al.Recent Advances in Photochemistry for Positron Emission Tomography Imaging[J]. Chinese Chemical Letters, 2024, 35(8): 109342.
[9] ZHANG Y, XU Z, YANG L, et al.Present Situation and Consideration of the Construction of Technical Standards for Radioisotope Products[J]. Journal of Isotopes(同位素), 2022, 35(2): 144-150.
[10] LI H, LIU Y, ZHANG QH, et al.Current Situation and Reflection of Radiopharmaceuticals[J]. Central South Pharmacy(中南药学), 2022, 20(9): 2214-2216.
[11] State Administration of Science, Technology and Industry for National Defense. PRC. Circular of Issuing the Medium and Long-term Development Plan for Medical Isotopes (2021-2035)[EB/OL]. (2021-06-25)[2024-08-12]. https://www.sastind.gov.cn/n10086167/n10086216/c10405915/content.html.
[12] National Medical Products Administration. Opinions on Reforming and Improving the Evaluation and Approval Management System of Radioactive Drugs[EB/OL]. (2023-04-25)[2024-08-12]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20230425160128160.html.
[13] The People's Government of Sichuan Province. Opinions on Promoting High-Quality Development of the Nuclear Medical Industry[EB/OL]. (2027-07-25)[2024-08-12]. https://www.sc.gov.cn/10462/zfwjts/2024/7/25/01472cc977b94a2293c6e58018ac6d04.shtml.
[14] The People's Government of Yantai. Yantai Municipal People 's Government Office Notice on the Issuance of Yantai Medical Isotope Health Industry Development Plan( 2022-2025 )[EB/OL]. (2023-03-03)[2024-08-12]. https://www.yantai.gov.cn/art/2023/3/3/art_99961_33789.html.
[15] VBDATA. CN.2023 Nuclear Medicine Industry White Paper[EB/OL]. (2023-05-06)[2024-08-12]. https://www.vbdata.cn/1518908140.
[16] JIA JJ, ZHANG WZ, GONG QS, et al.Review and Suggestions on Quality Inspection of Fludeoxyglucose [¹⁸F] Injection Prepared by Medical Institutions[J]. Journal of Isotopes(同位素), 2023. 36(1): 77-82.
[17] JIA JJ, HUANG BB, SHI YQ, et al.Discussion on the Inspection of Radiopharmaceuticals under the New Special Drug Supervision Policy[J]. Chinese Journal of New Drugs(中国新药杂志), 2023, 32(3): 236-240.
[18] National Medical Products Administration. Notice on the Issuance of Regulations on the Administration of Preparation of Positron Radioactive Drugs by Medical Institutions[EB/OL]. (2006-01-05)[2024-08-12]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjylqx/20211027164200141.html.
[19] National Medical Products Administration. Notice on the Approval and Supervision of Radioactive Drug Production and Operation Enterprises[EB/OL]. (2021-08-25) [2024-08-12]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20210825170157175.html.
[20] KUANG YW, DU JD, DU J, et al.Changes and Countermeasure Analysis of Radiopharmaceuticals Regulatory Regulations after the Implementation of the New “Pharmaceutical Administration Law”[J].Chinese Pharmaceutical Affairs(中国药事), 2023, 37(6): 659-663.
[21] WANG H, LIU Z, BAI X, et al.Synthesis of Dopamine Transporter Imaging Agent 11C-β-CFT and Its Application in the Diagnosis of Parkinson's Disease[J]. Journal of Molecular Imaging(分子影像学杂志), 2023, 46(4): 605-608.
[22] LI L, LIU FT, SUN YM, et al.Preliminary Study of [¹⁸F]-APN-1607 PET of Patients with Parkinsonism[J]. Chinese Journal of Clinical Neurosciences(中国临床神经科学), 2021, 29(6): 625-631.
[23] ZENG YP, JIANG GH, XIAO JM.¹⁸F-PSMA-1007 PET/MRI in the Diagnosis of Prostate Cancer[J]. Chinese Journal of Medical Imaging(中国医学影像学杂志), 2023, 31(5): 522-528.
[24] LI Z, WU Y, CHEN ZZ.The Value of ¹⁸F-PSMA-1007 PET/CT in the Early Diagnosis and Clinical Treatment of Patients with Biochemical Recurrence after Radical Prostatectomy[J]. China Oncology(中国癌症杂志), 2021, 31(11): 1081-1087.
[25] National Medical Products Administration. Notice on the Examination and Approval and Supervision of Radioactive Drug Production and Operation Enterprises[EB/OL]. (2022-03-23)[2024-08-12]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20210825170157175.html.
[26] PENG SM, YANG YC, YANG X, et al.Development Strategy for Innovation System of Radiopharmaceuticals in China[J]. Strategic Study of CAE(中国工程科学), 2022, 24(6): 116-126.
[27] EBNER R, LOHSE A, FABRITIUS MP, et al.Validation of the Standardization Framework SSTR-RADS 1.0 for Neuroendocrine Tumors Using the Novel SSTR-Targeting Peptide [¹⁸F] SiTATE[J]. European Radiology, 2024, 34(11): 7222-7232.
[28] WANG Y, CHEN Z, ZHU Y, et al.Total-body [⁶⁸Ga]Ga-PSMA-11 PET/CT Improves Detection Rate Compared with Conventional [⁶⁸Ga]Ga-PSMA-11 PET/CT in Patients with Biochemical Recurrent Prostate Cancer[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50(13): 4096-4106.
[29] PANG Y, ZHAO L, MENG TH, et al.PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using ⁶⁸Ga-FAP-2286: Comparison with ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 in a Single-Center, Prospective Study[J]. The Journal of Nuclear Medicine, 2023, 64(3): 386-394.
[30] AHMADI BN, GEVAERT T, DE SCHEPPER M, et al. Comparison of PSMA Immunohistochemistry Scoring Systems to Parametric [¹⁸F]PSMA-1007 PET/MRI in Primary Prostate Cancer[J/OL]. European Journal of Nuclear Medicine and Molecular Imaging, (2024-09-13)[2024-10-10]. https://doi.org/10.1007/s00259-024-06903-7.
[31] ZHAO L, PANG, YZ, ZHOU YF, et al, Antitumor Efficacy and Potential Mechanism of FAP-Targeted Radioligand Therapy Combined with Immune Checkpoint Blockade[J]. Signal Transduction and Targeted Therapy, 2024, 9(1): 142-142.
[32] HOTTA M, SONNI I, Thin P, et al.Visual and Whole-Body Quantitative Analyses of ⁶⁸Ga-DOTATATE PET/CT for Prognosis of Outcome After PRRT with ¹⁷⁷Lu-DOTATATE[J]. Annals of Nuclear Medicine, 2024, 38(4): 296-304.
[33] SIEBINGA H, DER VBJ, BEIJNEN JH, et al.Predicting [¹⁷⁷Lu]Lu-HA-DOTATATE Kidneyand Tumor Accumulation Based on [⁶⁸Ga]Ga-HA-DOTATATE Diagnostic Imaging Using Semi-physiological Population Pharmacokinetic Modeling[J]. EJNMMI physics, 2023, 10(1): 48.
[34] DIAS AH, JOCHUMSEN MR, ZACHO HD, et al.Multiparametric Dynamic Whole-Body PSMA PET/CT Using [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007[J]. EJNMMI Research, 2023, 13(1): 31.
[35] FONTI R, PANICO M, PELLEGRINO S, et al.Heterogeneity of SSTR2 Expression Assessed by ⁶⁸Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors[J]. The Journal of Nuclear Medicine, 2022, 63(10): 1509-1514.
[36] RATHKE H, WINTER E, BRUCHERTSEIFER F, et al.Deescalated 225Ac-PSMA-617 Versus ¹⁷⁷Lu/²²⁵Ac-PSMA-617 Cocktail Therapy: a Single-Center Retrospective Analysis of 233 Patients[J]. Journal of Nuclear Medicine, 2024, 65(7): 1057-1063.
[37] WANG J, LI SJ.A Brief Report on the Results of the National Survey of Nuclear Medicine in 2020[J]. Chinese Journal of Nuclear Medicine and Molecular Imaging(中华核医学与分子影像杂志), 2020, 40(12): 747-749.
[38] U.S. Food and Drug Administration. Drugs[EB/OL]. (2022-03-23)[2024-08-12]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process .
[39] National Medical Products Administration. Measures for the Administration of Radioactive Drugs[EB/OL].(2022-03-29)[2024-08-12]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20230328171235176.html.
[40] ZHANG KY, XING YZ, SHENG ZX, et al.Optimization of the Planar Model for Dose Distribution of Radioactive 125I Seed Plane Implantation[J]. Chinese Journal of Radiological Health(中国辐射卫生), 2019, 28(5): 590-593.
[41] Ministry of Transport of the People's Republic of China. Decision of the Ministry of Transport on Amending the Regulations on the Administration of Road Transport of Radioactive Materials[EB/OL]. (2023-12-04)[2028-08-12]. https://xxgk.mot.gov.cn/jigou/fgs/202312/t20231204_3961953.html.
[42] National Medical Products Administration. Announcement on the Issuance of the Assessment Procedures for the Inspection Institutions for Technetium Labeled and Positron Radiopharmaceuticals ( No.21, 2024 )[EB/OL]. (2024-03-07)[2024-08-12]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20240314175242120.html.